Myriad to Perform BRCA Testing in CDx Deal with Tesaro

Posted by Leanne Kodsman on

Taken from the Genetic Engineering and Biotechnology News clip:

Less than two weeks afterthe Supreme Court struck down its gene patents,Myriad Geneticshas moved on, inking an agreement withcancer-focused biopharmaceutical companyTesaroto conductBRCA1andBRCA2mutation testing on patients to be enrolled in two separate Phase III clinical studies evaluating the PARP inhibitorniraparib.


Taken from the Genetic Engineering and Biotechnology News clip:

Less than two weeks afterthe Supreme Court struck down its gene patents,Myriad Geneticshas moved on, inking an agreement withcancer-focused biopharmaceutical companyTesaroto conductBRCA1andBRCA2mutation testing on patients to be enrolled in two separate Phase III clinical studies evaluating the PARP inhibitorniraparib.

Tesaro's two Phase III clinical studies on niraparib include one in platinum-sensitive, high-grade serousovarian cancer patients, which is planned to begin enrolling patients in mid-2013; the other, involving metastaticbreast cancer patients who have germline BRCA mutations, is slated to begin during second half of 2013. Myriad's BRACAnalysistest, which can be used to detect BRCA1 or BRCA2 mutations,will be used as a companion diagnostic to identify patients for these clinical trials.

"We believe this agreement reinforces BRACAnalysis as the gold standard companion diagnostic test for this exciting new class of therapeutics," said Peter Meldrum, president and CEO of Myriad Genetics. "This collaboration is yet another example of Myriad's strong commitment to becoming a leader in the field ofcompanion diagnostics."


    Innovative Research was established in 1998 after the realization that dependable, high-quality, and affordable research materials were hard to come by. Starting with core products like human plasma and serum, Innovative Research has grown to be a trusted supplier of all lab reagents, including human biologicals and ELISA kits. Today, we manufacture and supply thousands of high-quality human and animal biologicals including plasma, serum, tissues, and proteins.


Related Posts

Innovative Research, Inc. Acquires Molecular Innovations, Inc.
Novi, MI, October 1, 2021 - Innovative Research, Inc. has finalized its agreement to ac...
Read the Article
And the winner is...
It is now time to announce that the $10,000 Grant for Post-Doctorate Research in the Li...
Read the Article
NEW! Synthetic CSF Now Available
Synthetic Human Cerebrospinal Fluid (CSF) from Innovative Research has been prepared us...
Read the Article

← Older Post Newer Post →

×